
BTL, the innovator in medical and aesthetic technologies, introduced the EXOMIND, powered by ExoTMS technology - a state-of-the-art, non-invasive brain stimulation treatment designed to improve mental and emotional well-being.
FDA-cleared for the treatment of depression, the EXOMIND’s patented ExoTMS technology comfortably stimulates key areas of the brain involved in emotional regulation, cognitive function and self-control. By activating neural pathways, it helps restore healthy brain activity and enhances neural connectivity.
Related: 2025 Wellness Treatment Trends You Need To Know About
"EXOMIND technology demonstrates our commitment to wellness by delivering natural, innovative solutions that empower individuals to reach their full potential," said Filip Donner, BTL's director. "This patient-friendly therapy aligns with our vision of promoting holistic health. Unlike conventional treatments, it provides a natural approach to mental wellness, fostering brain resilience without the side effects often associated with pharmaceuticals."
EXOMIND offers a pioneering treatment that appeals to patients seeking easy and drug-free alternatives. In clinical studies, patients appreciate EXOMIND's comfortable, walk-in, walk-out sessions lasting under 30 minutes. The device's ease of use allows for quick integration into medical practices, including family medicine and internal medicine practices.
"The majority of my patients are on some form of antidepressant medication. With EXOMIND, we now offer an alternative that enhances patient well-being and provides them with the freedom to manage their mental wellness without relying solely on medication," said Dr. Yael Halaas.